MENU

Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Version 1)

Qaseem, Amir; Yost, Jennifer; Etxeandia-Ikobaltzeta, Itziar; Miller, Matthew C.; Abraham, George M.; Obley, Adam Jacob; Forciea, Mary Ann; Jokela, Janet A.; Humphrey, Linda L.

ANNALS OF INTERNAL MEDICINE
2020
VL / 173 - BP / 137 - EP / +
abstract
KEY QUESTION 1 Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for Prophylaxis Against COVID-19? KEY QUESTION 2 Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for Treatment of COVID-19? BACKGROUND Using chloroquine or hydroxychloroquine, with or without azithromycin, to prevent coronavirus disease (COVID-19) after infection with novel coronavirus (SARS-CoV-2) or to treat COVID-19 began to receive attention following preliminary reports from in vitro (1) and human (2) studies. While multiple studies are planned or under way (3, 4), it is imperative to continually synthesize the results from the best available evidence to inform point-of-care decisions about the use of chloroquine or hydroxychloroquine. These practice points are based on a rapid and living systematic evidence review conducted by the University of Connecticut Health Outcomes, Policy, and Evidence Synthesis Group and will be updated as new evidence becomes available. The practice points development and update methods are included in the appendix, available at Annals.org. This version of the practice points, based on an evidence review conducted on 17 April 2020, was approved by the American College of Physicians Board of Regents on 4 May 2020 and submitted to Annals of Internal Medicine on 6 May 2020.

AccesS level

Green published

MENTIONS DATA